Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone)

Leuk Lymphoma. 2022 Jun;63(6):1508-1511. doi: 10.1080/10428194.2022.2032040. Epub 2022 Feb 2.

Authors

Ryosuke Naka¹, Kohei Tada¹, Hitomi Kaneko¹, Osamu Nagata¹, Masaharu Tashima¹, Chisato Mizutani¹, Kazunori Imada¹

Affiliation

¹ Japan Red Cross Osaka Hospital, Osaka, Japan.

PMID: 35105261
DOI: 10.1080/10428194.2022.2032040

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Carboplatin / therapeutic use
Cisplatin / therapeutic use
Deoxycytidine / analogs & derivatives
Dexamethasone / adverse effects
Gemcitabine
Humans
Lymphoma, Follicular* / diagnosis
Lymphoma, Follicular* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Non-Hodgkin* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Retrospective Studies
Rituximab / adverse effects
Salvage Therapy

Substances

Deoxycytidine
Rituximab
Dexamethasone
Carboplatin
Cisplatin
Gemcitabine